Tyrosine kinase inhibitors in EGFR-mutated large-cell neuroendocrine carcinoma of the lung? A case report

Case Reports in Oncology

Volumn 7, Issue 2, 2014, Pages 478-483

  Aroldi, Francesca ^a   Bertocchi, Paola ^a   Meriggi, Fausto ^a   Abeni, Chiara ^a   Ogliosi, Chiara ^a   Rota, Luigina ^a   Zambelli, Claudia ^a   Bnà, Claudio ^a   Zaniboni, Alberto ^a  

^a Vascular Surgery Unit Poliambulanza Foundation Hospital   (Italy)

Author keywords

Epidermal growth factor receptor mutation; Gefitinib; Large cell neuroendocrine carcinoma; Tyrosine kinase inhibitors

Indexed keywords

EID: 84924032070     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000365413     Document Type: Article

References (11)

1. Costanzo R, Montanino A, Di Maio M, Piccirillo MC, Sandomenico C, Giordano P, Daniele G, Franco R, Perrone F, Rocco G, Normanno N, Morabito A: Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Expert Rev Anticancer Ther 2013;13:1207-1218
2. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500
3. Araki J, Okamoto I, Suto R, Ichikawa Y, Sasaki J: Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. Lung Cancer 2005;48:141-144
4. Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M: EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 2006;17:1028-1029
5. Hiroshima K, Iyoda A, Shida T, Shibuya K, Iizasa T, Kishi H, Tanizawa T, Fujisawa T, Nakatani Y: Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol 2006;19:1358-1368
6. Iyoda A, Hiroshima K, Moriya Y, Mizobuchi T, Otsuji M, Sekine Y, Shibuya K, Iizasa T, Saitoh Y, Fujisawa T: Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. Ann Thorac Surg 2004;77:1891-1895; discussion 1895
7. Iyoda A, Makino T, Koezuka S, Otsuka H, Hata Y: Treatment options for patients with large cell neuroendocrine carcinoma of the lung. Gen Thorac Cardiovasc Surg 2014;62:351-356
8. De Pas TM, Giovannini M, Manzotti M, Trifirò G, Toffalorio F, Catania C, Spaggiari L, Labianca R, Barberis M: Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J Clin Oncol 2011;29:e819-e822
9. Yamazaki S, Sekine I, Matsuno Y, Takei H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Asamura H, Tsuchiya R, Saijo N: Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 2005;49:217-223
10. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM: Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005;11:3750-3757
11. Le Treut J, Sault MC, Lena H, Souquet PJ, Vergnenegre A, Le Caer H, Berard H, Boffa S, Monnet I, Damotte D, Chouaid C: Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol 2013;24:1548-1552.